Skip to main content
SpringerLink
Log in

Afatinib/osimertinib

Drug resistance, loss of appetite and nausea: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Song Z, et al. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review. Annals of Palliative Medicine 11: 1126-1134, No. 3, Mar 2022. Available from: URL: http://doi.org/10.21037/apm-21-3731

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/osimertinib. Reactions Weekly 1921, 17 (2022). https://doi.org/10.1007/s40278-022-22011-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-22011-2

Search

Navigation